Product
Standard ADT
Aliases
Standard ADT (androgen deprivation therapy)
2 clinical trials
2 indications
Clinical trial
A Randomized, Double-blind, Placebo Controlled Phase III Study of Darolutamide (ODM-201) Versus Placebo in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Patients With Metastatic Hormone Sensitive Prostate CancerStatus: Completed, Estimated PCD: 2021-10-25
Clinical trial
A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPCStatus: Recruiting, Estimated PCD: 2025-02-01